Psychiatr. praxi. 2013;14(1):30-33

Cipralex oral drops in treating agitation in elderly with dementia

MUDr.Vanda Franková, MUDr.Daniela Mojhová, MUDr.Jana Nyklesová, MUDr.Silvia Svaková
Psychiatrická léčebna Dobřany

Agitation is a very frequent behavioral manifestation of dementia. Antipsychotic drugs are used in pharmacotherapy; they are, however,

associated with a significant risk of adverse effects. Theoretical assumptions as well as clinical experience show a good effect of

selective serotonin reuptake inhibitors in this indication. At the gerontopsychiatric ward of a mental hospital, we studied the efficacy

and tolerability of escitalopram drops (Cipralex 20 mg/ml oral drops, solution) in 38 patients with dementia hospitalized for agitation as

well as other behavioral disorders. We were surprised by a rapid onset of action (from day 3 of use), excellent tolerability, and effect of

the medication (significant improvement in 28 patients).

Keywords: agitation, dementia, problem behavior, SSRI, serotonin, escitalopram

Published: December 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Franková V, Mojhová D, Nyklesová J, Svaková S. Cipralex oral drops in treating agitation in elderly with dementia. Psychiatr. praxi. 2013;14(1):30-33.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cohen-Mansfield J, Billig N. Agitated behaviors in the elderly: I. A conceptual review. Journal of the American Geriatrics Society 1986; (34): 711-721. Go to original source... Go to PubMed...
    2. Franková V, Hort J, Holmerová I, Jirák R, Vyhnálek M. Alzheimerova demence v praxi. Praha: Mladá fronta; 2011.
    3. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. American Journal of Geriatric Psych. 2006; 14(3): 191. Go to original source... Go to PubMed...
    4. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: metaanalysis of randomized placebo-controlled trials. JAMA: the journal of the American Medical Association 2005; 294(15): 1934-1943. Go to original source... Go to PubMed...
    5. Corbett A, Ballard C. Antipsychotics and Mortality in Dementia. American Journal of Psychiatry 2012; 169(1): 7-9. Go to original source... Go to PubMed...
    6. Vigen CLP, Mack WJ, Keefe RSE, Sano M, Sultzer DL, Stroup TS, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. American Journal of Psychiatry 2011; 168(8): 831-839. Go to original source... Go to PubMed...
    7. Ballard C, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1. Go to original source...
    8. Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, et al. Management of agitation and aggression associated with Alzheimer disease. Nature Reviews Neurology 2009; 5(5): 245-255. Go to original source... Go to PubMed...
    9. Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nature Reviews Neuroscience 2006; 7(6): 492-500. Go to original source... Go to PubMed...
    10. Alexopoulos GS, Jeste D, Chung H, Carpenter D, Ross R, Docherty J. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary. Postgraduate medicine 2005.
    11. Jirák R, Franková V. Demence. In: Psychiatrie, doporučené postupy psychiatrické péče III. Raboch J, Anders M, Hellerová P, Uhlíková P, eds. Praha: Tribun EU; 2010. p. 20-53.
    12. Gauthier S, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P, et al. Management of behavioral problems in Alzheimer's disease. International Psychogeriatrics 2010; 22(03): 346-372. Go to original source... Go to PubMed...
    13. Gorwood P, Weiller E, Lemming O, Katona C. Escitalopram prevents relapse in older patients with major depressive disorder. American Journal of Geriatric Psych. 2007; 15(7): 581-593. Go to original source... Go to PubMed...
    14. Wu E, Greenberg PE, Yang E, Yu A, Haim Erder M. Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population. Current Medical Research and Opinion(R). 2008; 24(9): 2587-2595. Go to original source... Go to PubMed...
    15. Lai M, Tsang S, Alder J, Keene J, Hope T, Esiri M, et al. Loss of serotonin 5-HT 2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease. Psychopharmacology 2005; 179(3): 673-677. Go to original source... Go to PubMed...
    16. Mintzer JE, Brawman-Mintzer O. Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: Toward a treatment approach. J Clin Psychiatry 1996; (57(suppl 7): 55-63.
    17. Lyketsos CG, Steele C, Galik E, Rosenblatt A, Steinberg M, Warren A, et al. Physical aggression in dementia patients and its relationship to depression. The American journal of psychiatry 1999; (156): 66-71. Go to original source... Go to PubMed...
    18. Lanctot KL, Herrmann N, Mazzotta P. Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci. 2001(13): 5-21. Go to original source... Go to PubMed...
    19. Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A, et al. Comparison of citalopram, perphanezine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. The American journal of psychiatry 2002; (159): 460-465. Go to original source... Go to PubMed...
    20. Pollock BG, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. American Journal of Geriatric Psych. 2007; 15(11): 942-952. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.